Login
Home / CUBT : OTC
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Curative Biotechnology, Inc.

$0.88 +$0.14 (+18.79%)
OTC · 14 Sep 2026 18:40 UTC
Previous Close
$1
Day Range
$0.88 - $0.88
Year Range
$0.03$1.99
Market Cap
6.02M
AVG Volume
1.14K
Trailing/Forward PE
-2.18/-
PEG ratio
-0.07
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (USD)
00.250.50.75124 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Net Income (USD)
-1M-750K-500K-250K024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Operating Income (USD)
-800K-600K-400K-200K024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
EBITDA (USD)
-800K-600K-400K-200K024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Cash Flows (USD)
-600K-400K-200K024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
EPS (USD)
-0.2-0.15-0.1-0.05-024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Expenses (USD)
-200K0200K400K600K800KR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Cash & Debt (USD)
01M2M3M4MCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Debt ratios
-2-1.5-1-0.5024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Margins
-300%-200%-100%0%100%11 Q412 Q112 Q212 Q312 Q413 Q113 Q213 Q313 Q414 Q1
Return on Capital
0%10%20%30%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Shares Outstanding
02.5M5M7.5M10M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Book Value Per Share (USD)
-1-0.75-0.5-0.25024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Total Assets (USD)
01M2M3M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PE Ratio
020406080100med 12.93Apr 20Jun 20Aug 20Oct 20Dec 20Jan 21Mar 21
Free Cash Flow Yield
-25%-20%-15%-10%-5%0%med -10.37%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Price to Sales
0100200300400med 0.12Jul 18Oct 18Feb 19May 19Aug 19Dec 19Mar 20
EV/EBITDA
020406080100med 12.73Apr 20Jun 20Aug 20Oct 20Dec 20Jan 21Mar 21
Price to Book
0100020003000med 29.18Jul 20Oct 20Dec 20Aug 21Nov 21Jan 22Mar 22
Curative Biotechnology, Inc.
CUBT
Stockpicker

Video analysis: CUBT

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: CUBT

Curative Biotechnology, Inc. Issues Letter to Shareholders

globenewswire.com · 11 Sep 2026

Curative Biotechnology, Inc. Issues Letter to Shareholders

Company Reviews Significant Ophthalmology, Intellectual Property and Translational Development Milestones Achieved Over the Past Year Palm Beach Gardens, FL, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative" or the "Company"), a development-stage biomedical company advancing topical metformin-based ophthalmic therapies for degenerative eye diseases, today issued the following letter to shareholders and interested investors reviewing the Company's progress over the past year and outlining its priorities as it advances its ophthalmology platform.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.